Subscribe
Air Force Lt. Col. Penny Vroman, Brooke Army Medical Center Nuclear Medicine Department chief, looks at scans of a patient with neuroendocrine tumors June 26, 2019 to see if the radiopharmaceutical drug is targeting the tumors. The use of lutetium Lu 177 dotatate was approved by the Food and Drug Administration in January 2018 for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults. (U.S. Army photo by Lori Newman)
| Date Taken: | 06.26.2019 |
| Date Posted: | 06.28.2019 08:54 |
| Photo ID: | 5538984 |
| VIRIN: | 190626-A-SR136-1003 |
| Resolution: | 3008x2000 |
| Size: | 1.62 MB |
| Location: | FORT SAM HOUSTON, TEXAS, US |
| Web Views: | 29 |
| Downloads: | 3 |
This work, BAMC offers new treatment option for certain types of tumors [Image 3 of 3], by Lori Newman, identified by DVIDS, must comply with the restrictions shown on https://www.dvidshub.net/about/copyright.
BAMC offers new treatment option for certain types of tumors
No keywords found.
